These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15518744

  • 1. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation?
    Lai WJ, Chiang YJ, Chen Y, Chu SH.
    Transplant Proc; 2004 Sep; 36(7):2056-7. PubMed ID: 15518744
    [Abstract] [Full Text] [Related]

  • 2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus in chronic allograft nephropathy.
    Wu MJ, Shu KH, Cheng CH, Chen CH.
    Transplant Proc; 2004 Sep; 36(7):2053-5. PubMed ID: 15518743
    [Abstract] [Full Text] [Related]

  • 5. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M.
    Transplant Proc; 2006 Sep; 38(1):101-4. PubMed ID: 16504675
    [Abstract] [Full Text] [Related]

  • 6. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

  • 7. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
    Kahan BD.
    Transplantation; 2001 Jun 15; 71(11 Suppl):SS52-7. PubMed ID: 11583490
    [Abstract] [Full Text] [Related]

  • 8. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 9. The effect of sirolimus in the development of chronic allograft nephropathy.
    Gürkan A, Kaçar S, Erdoğdu U, Varilsüha C, Kandemir G, Karaca C, Akman F.
    Transplant Proc; 2008 Nov 15; 40(1):114-6. PubMed ID: 18261561
    [Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 12. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience.
    Weber T, Abendroth D, Schelzig H.
    Transpl Int; 2005 Feb 27; 18(2):151-6. PubMed ID: 15691266
    [Abstract] [Full Text] [Related]

  • 13. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
    Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP.
    Transplantation; 2003 Apr 15; 75(7):998-1003. PubMed ID: 12698087
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 15. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Aug 15; 10(5):565-9. PubMed ID: 16856992
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus conversion experience in a single center.
    Wang HH, Huang JY, Chu SH, Chiang YJ, Liu KL, Lai PC.
    Transplant Proc; 2008 Sep 15; 40(7):2209-10. PubMed ID: 18790194
    [Abstract] [Full Text] [Related]

  • 17. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M, Liu S, Strobl M, Schmaderer C, Baumann M, Heemann U, Lutz J.
    Transplant Proc; 2008 Dec 15; 40(10):3731-6. PubMed ID: 19100477
    [Abstract] [Full Text] [Related]

  • 18. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy.
    Chen J, Li L, Wen J, Tang Z, Ji S, Sha G, Cheng Z, Sun Q, Cheng D, Liu Z.
    Transplant Proc; 2008 Jun 15; 40(5):1411-5. PubMed ID: 18589119
    [Abstract] [Full Text] [Related]

  • 19. [Therapeutic effect of sirolimus against chronic allograft nephropathy in kidney transplant recipients].
    Wang CX, Chen SY, Chen LZ, Liu LS, Fei JG, Deng SX, Qiu J, Li J, Zheng KL, Wu PG, Ji YL, Zhu LY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec 15; 27(12):1924-6. PubMed ID: 18159022
    [Abstract] [Full Text] [Related]

  • 20. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.